Positive Data But Uphill Struggle For Takeda’s Trelagliptin?
This article was originally published in PharmAsia News
Takeda has released the first detailed late-stage clinical results for trelagliptin, showing positive data for the once-weekly DPP-4 inhibitor, which is currently awaiting Japanese approval for type 2 diabetes. But a number of factors may play on the drug’s commercial prospects.
You may also be interested in...
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.